[Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].

Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia. Pirozadil seems more effective as a cholesterol-lowering agent. There were no adverse reactions. We conclude that pirozadil can be a valuable agent in preventing atherosclerotic disease.